Continuous glucose monitoring improves recovery in diabetic colorectal cancer patients

Enhanced recovery outcomes for colorectal cancer patients with type 2 diabetes markedly improved through continuous glucose monitoring (CGM). A study involving 181 patients revealed that those under CGM showed lower mean daily glucose levels (9.52 mmol/L) compared to conventional glucose monitoring (10.37 mmol/L) on postoperative day one. The technology significantly enhanced glycemic control and facilitated quicker recovery, wound healing, and early detection of hyperglycemia. These promising results endorse CGM’s integration in surgical management for this patient population.